1. Home
  2. XLO vs ECOR Comparison

XLO vs ECOR Comparison

Compare XLO & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XLO
  • ECOR
  • Stock Information
  • Founded
  • XLO 2016
  • ECOR 2005
  • Country
  • XLO United States
  • ECOR United States
  • Employees
  • XLO N/A
  • ECOR N/A
  • Industry
  • XLO Biotechnology: Pharmaceutical Preparations
  • ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • XLO Health Care
  • ECOR Health Care
  • Exchange
  • XLO Nasdaq
  • ECOR Nasdaq
  • Market Cap
  • XLO 40.9M
  • ECOR 40.0M
  • IPO Year
  • XLO 2021
  • ECOR 2018
  • Fundamental
  • Price
  • XLO $0.80
  • ECOR $5.04
  • Analyst Decision
  • XLO Buy
  • ECOR Strong Buy
  • Analyst Count
  • XLO 2
  • ECOR 2
  • Target Price
  • XLO $3.00
  • ECOR $25.50
  • AVG Volume (30 Days)
  • XLO 604.4K
  • ECOR 41.6K
  • Earning Date
  • XLO 11-07-2025
  • ECOR 11-05-2025
  • Dividend Yield
  • XLO N/A
  • ECOR N/A
  • EPS Growth
  • XLO N/A
  • ECOR N/A
  • EPS
  • XLO N/A
  • ECOR N/A
  • Revenue
  • XLO $15,001,000.00
  • ECOR $27,700,000.00
  • Revenue This Year
  • XLO $519.70
  • ECOR $23.74
  • Revenue Next Year
  • XLO $44.57
  • ECOR $42.02
  • P/E Ratio
  • XLO N/A
  • ECOR N/A
  • Revenue Growth
  • XLO 536.45
  • ECOR 30.16
  • 52 Week Low
  • XLO $0.62
  • ECOR $4.16
  • 52 Week High
  • XLO $1.70
  • ECOR $19.49
  • Technical
  • Relative Strength Index (RSI)
  • XLO 52.39
  • ECOR 50.60
  • Support Level
  • XLO $0.73
  • ECOR $4.88
  • Resistance Level
  • XLO $0.90
  • ECOR $5.19
  • Average True Range (ATR)
  • XLO 0.06
  • ECOR 0.23
  • MACD
  • XLO 0.00
  • ECOR 0.01
  • Stochastic Oscillator
  • XLO 41.23
  • ECOR 59.91

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).

About ECOR electroCore Inc.

electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.

Share on Social Networks: